Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Arcutis launched a new virtual health platform to expand access to its ZORYVE portfolio for chronic inflammatory skin diseases like eczema and psoriasis. The digital offering connects patients with independent board-certified dermatologists, aiming to reduce barriers such as long wait times and geographic limitations.
Key figures
- Addressable population us
- more than 45 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.